Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 11879161)

1.

Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.

Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB, Russell JM, Hirschfeld RM, LaVange LM, Klein DN, Fawcett J, Harrison W.

Arch Gen Psychiatry. 2002 Mar;59(3):233-9.

PMID:
11879161
2.

CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study.

Probst-Schendzielorz K, Scholl C, Efimkina O, Ersfeld E, Viviani R, Serretti A, Fabbri C, Gurwitz D, Lucae S, Ising M, Paul AM, Lehmann ML, Steffens M, Crisafulli C, Calabrò M, Holsboer F, Stingl J.

Pharmacogenomics. 2015 May;16(7):689-701. doi: 10.2217/pgs.15.31. Epub 2015 May 6.

PMID:
25943212
3.

An unusual cause of esophageal ulcer; sertraline hydrochloride.

Dağ MS, Koruk İ, Aydınlı M, Çam H, Öztürk ZA, Kadayıfçı A.

Turk J Gastroenterol. 2014 Dec;25 Suppl 1:250-1. doi: 10.5152/tjg.2014.4646. No abstract available.

4.

A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.

Etkin A, Patenaude B, Song YJ, Usherwood T, Rekshan W, Schatzberg AF, Rush AJ, Williams LM.

Neuropsychopharmacology. 2015 May;40(6):1332-42. doi: 10.1038/npp.2014.333. Epub 2014 Dec 30.

PMID:
25547711
5.

Antidepressant treatment of melancholia in older adults.

Sneed JR, Reinlieb ME, Rutherford BR, Miyazaki M, Fitzsimons L, Turret N, Pelton GH, Devanand DP, Sackeim HA, Roose SP.

Am J Geriatr Psychiatry. 2014 Jan;22(1):46-52. doi: 10.1016/j.jagp.2013.02.001. Epub 2013 Oct 8.

PMID:
24119858
6.

Treatment course with antidepressant therapy in late-life depression.

Irion KL, Muly S, Hochhegger B, Marchiori E.

Am J Psychiatry. 2013 Apr;170(4):446. doi: 10.1176/appi.ajp.2013.12121544. No abstract available.

PMID:
23545799
7.

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.

J Clin Psychiatry. 2012 Jul;73(7):984-91. doi: 10.4088/JCP.11m07230.

PMID:
22901348
8.

Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.

Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, Stürmer T.

J Clin Psychopharmacol. 2012 Feb;32(1):114-9. doi: 10.1097/JCP.0b013e31823f705d.

PMID:
22198447
9.

Sertraline and low-dose doxepin treatment in severe agitated-anxious depression with significant gastrointestinal complaints:two case reports.

Maclean L, Ahmedani BK.

Prim Care Companion CNS Disord. 2011;13(4). pii: PCC.10l01152. doi: 10.4088/PCC.10l01152. No abstract available.

10.

Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?

Gaynes BN, Farley JF, Dusetzina SB, Ellis AR, Hansen RA, Miller WC, Stürmer T.

Depress Anxiety. 2011 Nov;28(11):989-98. doi: 10.1002/da.20898. Epub 2011 Sep 2.

11.

Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial.

Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, Takeuchi H, Abe T, Kashima H, Mimura M.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1983-9. doi: 10.1016/j.pnpbp.2011.08.008. Epub 2011 Aug 24.

PMID:
21889560
12.

Managing antidepressants in primary care: physicians' treatment modifications.

Tamburrino MB, Nagel RW, Lynch DJ.

Psychol Rep. 2011 Jun;108(3):799-804.

PMID:
21879626
13.
14.

Multicentric efficacy study of centpropazine and imipramine in depressed patients.

Srivastava JS, Asthana OP, Singh H, Agarwal AK, Shah LP, Sharma KC, Gopinath PS, Srimal RC.

Indian J Psychiatry. 1999 Jul;41(3):249-53.

15.

Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response.

Wolkowitz OM, Mellon SH, Epel ES, Lin J, Reus VI, Rosser R, Burke H, Compagnone M, Nelson JC, Dhabhar FS, Blackburn EH.

Mol Psychiatry. 2012 Feb;17(2):164-72. doi: 10.1038/mp.2010.133. Epub 2011 Jan 18.

16.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
17.

Antidepressant pharmacotherapy in adults with type 2 diabetes: rates and predictors of initial response.

Anderson RJ, Gott BM, Sayuk GS, Freedland KE, Lustman PJ.

Diabetes Care. 2010 Mar;33(3):485-9. doi: 10.2337/dc09-1466. Epub 2009 Dec 23.

18.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
19.
20.

Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression.

Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, Gallop R.

J Consult Clin Psychol. 2009 Aug;77(4):775-87. doi: 10.1037/a0015401.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk